Celldex cancer vax could be fast-tracked; Prof who falsified HIV vaccine data gets prison sentence;

> Celldex's ($CLDX) cancer vaccine, Rintega, could be fast-tracked. Joseph Pantginis and Assaf Vestin of Roth Capital Partners predicted it will be the second cancer vaccine approved in the U.S. More

> Dong Pyou Han, who falsified HIV vaccine research, was sentenced to more than four and a half years in prison and ordered to repay $7.2 million in grants his team received from the federal government. Story

> India's Hilleman Labs announced it has made a breakthrough in its quest for an affordable Haemophilus influenzae type B (Hib) vaccine. Report

> The Indian government has called on the private sector to help develop cost-effective vaccines to boost its immunization program. Article

> Siemens and BioNTech are collaborating to produce personalized cancer vaccines on a commercial scale. News

Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.